Literature DB >> 8676515

Characterization of a soluble stable human cytomegalovirus protease and inhibition by M-site peptide mimics.

R L LaFemina1, K Bakshi, W J Long, B Pramanik, C A Veloski, B S Wolanski, A I Marcy, D J Hazuda.   

Abstract

The human cytomegalovirus (HCMV) protease is a potential target for antiviral chemotherapeutics; however, autoprocessing at internal sites, particularly at positions 143 and 209, hinders the production of large quantities of stable enzyme for either screening or structural studies. Using peptides encompassing the sequence of the natural M-site substrate (P5-P5', GVVNA/SCRLA), we previously demonstrated that substitution of glycine for valine at the P3 position in the substrate abrogates processing by the recombinant protease in vitro. We now demonstrate that introduction of the V-to-G substitution in the P3 positions of the two major internal processing sites, positions 143 and 209, in the mature HCMV protease renders the enzyme stable to autoprocessing. When expressed in Escherichia coli, the doubly substituted protease was produced almost exclusively as the 30-kDa full-length protein. The full-length V141G, V207G (V-to-G changes at positions 141 and 207) protease was purified as a soluble protein by a simple two-step procedure, ammonium sulfate precipitation followed by DEAE ion-exchange chromatography, resulting in 10 to 15 mg of greater than 95% pure enzyme per liter. The stabilized enzyme was characterized kinetically and was indistinguishable from the wild-type recombinant protease, exhibiting Km and catalytic constant values of 0.578 mM and 13.18/min, respectively, for the maturation site (M-site) peptide substrate, GVVNASCRLARR (underlined residues indicate additions to or substitutions from peptides derived from the wild-type substrate). This enzyme was also used to perform inhibition studies with a series of truncated and/or substituted maturation site peptides. Short nonsubstrate M-site-derived peptides were demonstrated to be competitive inhibitors of cleavage in vitro, and these analyses defined amino acids VVNA, P4 through P1 in the substrate, as the minimal substrate binding and recognition sequence for the HCMV protease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676515      PMCID: PMC190425     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Cytomegalovirus assembly protein nested gene family: four 3'-coterminal transcripts encode four in-frame, overlapping proteins.

Authors:  A R Welch; L M McNally; W Gibson
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate.

Authors:  F Y Liu; B Roizman
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

3.  The complete sequence of the capsid p40 gene from infectious laryngotracheitis virus.

Authors:  A M Griffin
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

Review 4.  Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169.

Authors:  M S Chee; A T Bankier; S Beck; R Bohni; C M Brown; R Cerny; T Horsnell; C A Hutchison; T Kouzarides; J A Martignetti
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

5.  Identification of precursor to cytomegalovirus capsid assembly protein and evidence that processing results in loss of its carboxy-terminal end.

Authors:  W Gibson; A I Marcy; J C Comolli; J Lee
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  Primate cytomegalovirus assembly: evidence that DNA packaging occurs subsequent to B capsid assembly.

Authors:  J Y Lee; A Irmiere; W Gibson
Journal:  Virology       Date:  1988-11       Impact factor: 3.616

7.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

8.  Vectors for selective expression of cloned DNAs by T7 RNA polymerase.

Authors:  A H Rosenberg; B N Lade; D S Chui; S W Lin; J J Dunn; F W Studier
Journal:  Gene       Date:  1987       Impact factor: 3.688

Review 9.  The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1.

Authors:  D J McGeoch; M A Dalrymple; A J Davison; A Dolan; M C Frame; D McNab; L J Perry; J E Scott; P Taylor
Journal:  J Gen Virol       Date:  1988-07       Impact factor: 3.891

10.  Isolation of human cytomegalovirus intranuclear capsids, characterization of their protein constituents, and demonstration that the B-capsid assembly protein is also abundant in noninfectious enveloped particles.

Authors:  A Irmiere; W Gibson
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

View more
  3 in total

1.  Cleavage of human cytomegalovirus protease pUL80a at internal and cryptic sites is not essential but enhances infectivity.

Authors:  Amy N Loveland; Chee-Kai Chan; Edward J Brignole; Wade Gibson
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 2.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

3.  Cytomegalovirus protease targeted prodrug development.

Authors:  Hairat Sabit; Arik Dahan; Jing Sun; Chester J Provoda; Kyung-Dall Lee; John H Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-03-20       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.